Formulation batch manufacturing for oral direct compression tablets is one of the most widely adopted and cost-efficient methods in modern pharmaceutical development. Direct compression offers precision, scalability, and regulatory compliance, making it the preferred choice for stability studies, clinical trial batches, and eventual commercial scale-up. In this detailed article, we will outline the objectives, responsibilities, process flow, analytical testing, packaging, stability requirements, transportation, and documentation deliverables that ensure full compliance with cGMP, ICH, and regulatory standards.

Ukraine Product List

Generic NameGeneric BrandStrengthDosage FormPackingTherapeutic Category
Levofloxacin—500 mgTablet10 TabletsAntibiotic (Fluoroquinolone)
Levofloxacin—250 mgTablet10 TabletsAntibiotic (Fluoroquinolone)
Ciprofloxacin—500 mgTablet30 TabletsAntibiotic (Fluoroquinolone)
Ambroxol—30 mgTablet20 TabletsExpectorant/Mucolytic
Amlodipine—5 mgTablet20 TabletsAntihypertensive (Calcium Channel Blocker)
Amlodipine—10 mgTablet30 TabletsAntihypertensive (Calcium Channel Blocker)
Captopril—25 mgTablet20 TabletsAntihypertensive (ACE Inhibitor)
Captopril—50 mgTablet20 TabletsAntihypertensive (ACE Inhibitor)
Enalapril—10 mgTablet30 TabletsAntihypertensive (ACE Inhibitor)
Enalapril—20 mgTablet30 TabletsAntihypertensive (ACE Inhibitor)
Lisinopril—10 mgTablet30 TabletsAntihypertensive (ACE Inhibitor)
Pregabalin—75 mgCapsule30 CapsulesNeuropathic Pain/Anticonvulsant
Pregabalin—150 mgCapsule30 CapsulesNeuropathic Pain/Anticonvulsant
Pregabalin—300 mgCapsule30 CapsulesNeuropathic Pain/Anticonvulsant
Xylometazoline—0.1%Nasal Drops10 ml BottleNasal Decongestant
Ranitidine—150 mgTablet100 TabletsAntiulcer (H2 Blocker)
Ranitidine—150 mgTablet20 TabletsAntiulcer (H2 Blocker)
Domperidone—10 mgTablet30 TabletsAntiemetic/Prokinetic
Domperidone—10 mgTablet60 TabletsAntiemetic/Prokinetic
Simvastatin—20 mgTablet30 TabletsLipid-lowering (Statin)
Simvastatin—20 mgTablet60 TabletsLipid-lowering (Statin)
Simvastatin—40 mgTablet30 TabletsLipid-lowering (Statin)
Simvastatin—40 mgTablet60 TabletsLipid-lowering (Statin)
Diclofenac—1%Gel30 g TubeNSAID (Topical)
Diclofenac—50 mgTablet20 TabletsNSAID (Analgesic)
Diclofenac—100 mgTablet20 TabletsNSAID (Analgesic)
Paracetamol + Diclofenac—500 mg + 50 mgTablet10 TabletsAnalgesic/Antipyretic + NSAID
Ibuprofen—100/5Dry Syrup100 ml BottleNSAID (Analgesic/Antipyretic)
Ibuprofen—100/5Dry Syrup200 ml BottleNSAID (Analgesic/Antipyretic)
Ibuprofen—200/5Dry Syrup100 ml BottleNSAID (Analgesic/Antipyretic)
Paracetamol—500 mgTablet10 TabletsAnalgesic/Antipyretic
Metronidazole—250 mgTablet20 TabletsAntiprotozoal/Antibacterial
Carvedilol—12.5 mgTablet30 TabletsAntihypertensive (Beta Blocker)
Carvedilol—25 mgTablet30 TabletsAntihypertensive (Beta Blocker)
Loperamide—2 mgTablet20 TabletsAntidiarrheal
Bisoprolol—5 mgTablet30 TabletsAntihypertensive (Beta Blocker)
Bisoprolol—10 mgTablet30 TabletsAntihypertensive (Beta Blocker)
Azithromycin—500 mgTablet3 TabletsAntibiotic (Macrolide)
Itraconazole—100 mgCapsule100 CapsulesAntifungal
Clopidogrel—75 mgTablet100 TabletsAntiplatelet
Cefepime—1 gInjection (Vial)1 VialAntibiotic (Cephalosporin)
Ceftriaxone—1 gInjection (Vial)1 VialAntibiotic (Cephalosporin)
Cefixime—400 mgTablet—Antibiotic (Cephalosporin)
Risperidone—1, 2, 3, 4 mgTablet—Antipsychotic
Loperamide—2 mgCapsule—Antidiarrheal
Amoxiclav—1.2 gInjection (Vial)1 VialAntibiotic (Beta-lactam + Clavulanic acid)

Chile Product List

Generic NameGeneric BrandStrengthDosage FormPackingTherapeutic Category
Risperidone—1 mg, 3 mgTablet—Antipsychotic
Lithium Carbonate—300 mgTablet—Mood Stabilizer
Hydroxychloroquine—200 mgTablet—Antimalarial/Immunomodulator
Ursodeoxycholic Acid——Tablet—Hepatoprotective

Costa Rica Product List

Generic NameGeneric BrandStrengthDosage FormPackingTherapeutic Category
Carbamazepine CR—200 mgTablet (CR)—Anticonvulsant
Mesalamine—1 gSuppository—Anti-inflammatory (IBD)
Montelukast Sodium—5 mgTablet—Antiasthmatic (Leukotriene Antagonist)

Philippines Product List

Generic NameGeneric BrandStrengthDosage FormPackingTherapeutic Category
Labetalol—100 mg, 200 mgTablet—Antihypertensive (Beta Blocker)
Sumatriptan + Naproxen—50 mg + 275 mgTablet—Antimigraine
Gabapentin—100 mgCapsule—Anticonvulsant/Neuropathic Pain

Objective of Direct Compression Batch Manufacturing

The primary goal of oral direct compression batch manufacturing is to produce clinical, stability, and commercial validation batches with accuracy, reproducibility, and quality assurance. These batches are executed at Contract Manufacturing Organizations (CMOs) under stringent environmental and regulatory conditions. The objectives include:

  • Manufacturing tablets for stability studies, bioequivalence (BE)/pharmacokinetics (PK) trials, and commercial validation.
  • Maintaining compliance with cGMP guidelines, ICH Q8/Q9/Q10, and regulatory authority expectations.
  • Ensuring robustness of formulation to facilitate smooth technology transfer and eventual large-scale production.

Roles and Responsibilities in Batch Manufacturing

Customer Responsibilities

  • Provide an approved manufacturing formula and batch record.
  • Supply API specifications, excipients, and raw materials that meet pharmacopeial standards.
  • Define stability study protocols, product specifications, and testing methodologies.

CMO Responsibilities

  • Apply for required API import licenses and manufacturing approvals.
  • Manufacture the tablets strictly according to the approved master batch record (MBR).
  • Maintain strict environmental controls such as temperature and humidity in GMP areas.
  • Execute packaging, labeling, and stability studies in compliance with BENOC/ICH guidelines.
  • Provide batches for clinical dosing, validation, and commercial evaluation.

Formulation Batch Details

The size and strength of the batches are tailored to the development stage:

  • Pilot Batch (Stability): ~5,000 tablets
  • Clinical Batch: ~50,000 tablets
  • Commercial Validation Batch: 3 × 100,000 tablets

Strengths may vary across single or multiple dose levels. These batches are designated for stability studies, BE/PK trials, and validation activities.


Formulation Process for Direct Compression Tablets

Direct compression eliminates the need for granulation, making the process efficient and reproducible.

Stepwise Flow Chart:

  1. Raw Material Dispensing – Accurate weighing of API and excipients using calibrated balances.
  2. Sifting/Sieving – Removal of lumps and foreign particles to achieve uniform particle size.
  3. Blending – Homogeneous mixing of API with fillers, binders, and disintegrants.
  4. Lubricant Addition – Incorporation of lubricants like magnesium stearate for smooth compression.
  5. Compression – Conversion of blend into tablets using rotary compression machines.
  6. Primary Packaging – Packing into Alu-Alu blister packs under controlled conditions.

Tablet Specifications:

  • Round (6.5 mm or 7 mm)
  • Oval (13 × 7 mm)

Environmental Conditions:

  • Temperature: ≤ 30°C
  • Relative Humidity: 35% RH (up to 40% permissible)

Equipment Required:

  • Calibrated weighing balances
  • Rotary compression machine
  • High-shear or bin blender
  • Packing machine for blister/carton packaging
  • Roller compactor (only if excipients do not meet specifications)

Analytical Testing & Sample Management

Each batch undergoes rigorous analytical testing to ensure safety, efficacy, and compliance.

Key Analytical Tests:

  • Appearance (visual inspection for defects)
  • Assay (HPLC) for API content
  • Content Uniformity across tablets
  • Dissolution profile studies
  • Related Substances (impurities/degradants)
  • Water Content (Karl Fischer titration)
  • Microbial Limits (if applicable)
  • Stability-indicating Parameters

Sample Retention:

  • Stability Samples: Retained as per ICH Q1A guidelines.
  • Reference Samples: Retained for regulatory audits.
  • Retention Samples: Maintained as per GMP documentation requirements.

Packaging Requirements

Proper packaging ensures stability, compliance, and traceability of clinical and commercial batches.

  • Primary Packaging: Alu-Alu blisters (10’s or market-specific configuration).
  • Secondary Packaging: Printed cartons with leaflet inserts.
  • Clinical Labeling: As per IRB/regulatory standards with details such as batch number, storage conditions, expiry date, and usage instructions.
  • Commercial Packaging: Designed as per market-specific artwork and branding guidelines.

Stability Study Plan

Stability testing is essential to establish shelf life and storage conditions.

Conditions:

  • Long-term: 25°C ± 2°C / 60% ± 5% RH
  • Accelerated: 40°C ± 2°C / 75% ± 5% RH
  • Intermediate: 30°C ± 2°C / 65% ± 5% RH

Time Points:

  • 0, 1, 3, 6, 9, 12, 18, 24 months

Parameters Monitored:

  • Assay
  • Dissolution profile
  • Impurity profiling
  • Physical appearance
  • Moisture content
  • Microbial testing (if required)

Transport Requirements

Transport of both API and finished drug product (FDF) requires qualified logistics partners with validated systems.

  • Mode: Temperature-controlled vehicles with qualified couriers.
  • Conditions: API transported at 2–8°C, FDF transported at 15–25°C.
  • Data Logging: Mandatory during every shipment for temperature verification.
  • Packaging: Use of insulated shippers, validated gel packs, or phase change materials.

Documentation Deliverables

Comprehensive documentation is a regulatory prerequisite for every stage of manufacturing.

  • Master Batch Record (MBR) & Batch Manufacturing Record (BMR)
  • Certificates of Analysis (COA) for raw materials and finished products
  • Deviation and CAPA reports
  • Stability study protocols and interim reports
  • Transport validation reports

These deliverables not only ensure regulatory compliance but also facilitate audit readiness and smooth technology transfer.


The process of formulation batch manufacturing for oral direct compression tablets is a highly controlled and regulated activity, critical to pharmaceutical development and commercialization. From pilot and clinical batches to commercial validation, each stage demands robust processes, precise documentation, and compliance with international guidelines. By following best practices in formulation, testing, packaging, stability studies, and transportation, pharmaceutical companies can ensure successful product launches and patient safety worldwide.